Postapproval Cardio Studies Challenged By Enrollment, Protocol Issues
This article was originally published in The Gray Sheet
Executive Summary
FDA’s assessments of strengths and weaknesses for eight years’ worth of completed cardiovascular trials show about one-third of studies are challenged by enrollment, protocol or bias issues, according to a graphical analysis by "The Gray Sheet."